Canada Markets close in 6 hrs 17 mins
  • S&P/TSX

    20,754.96
    -7.07 (-0.03%)
     
  • S&P 500

    4,584.96
    +7.86 (+0.17%)
     
  • DOW

    34,681.66
    +41.87 (+0.12%)
     
  • CAD/USD

    0.7837
    +0.0029 (+0.3684%)
     
  • CRUDE OIL

    68.87
    +2.37 (+3.56%)
     
  • BTC-CAD

    72,305.43
    -655.97 (-0.90%)
     
  • CMC Crypto 200

    1,447.08
    +5.32 (+0.37%)
     
  • GOLD FUTURES

    1,771.90
    +9.20 (+0.52%)
     
  • RUSSELL 2000

    2,206.33
    +58.91 (+2.74%)
     
  • 10-Yr Bond

    1.4600
    +0.0120 (+0.83%)
     
  • NASDAQ

    15,346.95
    -34.37 (-0.22%)
     
  • VOLATILITY

    26.15
    -4.97 (-15.97%)
     
  • FTSE

    7,164.14
    +34.93 (+0.49%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • CAD/EUR

    0.6936
    +0.0031 (+0.45%)
     

NOVAVAX INVESTIGATED: The Klein Law Firm Announces an Investigation on Behalf of Novavax, Inc. Investors

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - October 25, 2021) - The Klein Law Firm has begun an investigation into Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX) concerning possible violations of federal securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Specifically, The Klein Law firm is investigating allegations relating to potential failure by the Company to disclose manufacturing and purity problems in its production process for Covid-19 vaccinations. An article published by Politico titled, "'They Rushed the Process': Vaccine Maker's woes hamper global inoculation campaign," stated that "manufacturing problems are jeopardizing billions of doses earmarked for poor and middle-income countries."

The Politico article was published after the market closed on October 19, 2021, and shares of Novavax fell over 20% in premarket trading on October 20, 2021.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the NVAX investigation, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link:

https://www.kleinstocklaw.com/pslra-1/novavax-inc-loss-submission-form



ABOUT KLEIN LAW FIRM

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100810

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting